Molecular Biomarkers & Diagnosis

Brian J. Czerniecki

Publications

• Research Article
  Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer
  Author(s): Lian Lam, Brian J. Czerniecki, Elizabeth Fitzpatrick, Shuwen Xu, Lynn Schuchter, Xiaowei Xu and Hongtao ZhangLian Lam, Brian J. Czerniecki, Elizabeth Fitzpatrick, Shuwen Xu, Lynn Schuchter, Xiaowei Xu and Hongtao Zhang
  
  Over-expression of the HER2/neu receptor occurs in 20 to 30 percent of breast tumors and is linked to poorer prognosis. The HER2/neu expression status determines whether or not patient will receive trastuzumab- based treatment. In clinical practice, over-expression of HER2/neu is routinely identified using Immunohistochemistry (IHC) or Fluorescence in Situ Hybridization (FISH), both of which are invasive approaches requiring tissue samples. Serum assays for the Extra Cellular Domain of HER2/neu receptor (HER2 ECD) have been reported but the use is very limited due to serum interference factors (e.g. human anti-animal immunoglobulin antibodies) that lead to false test results and inconsistency with tissue Her2 status. We have developed an ELISA based approach using an MBB buffer to eliminate false results and to obtain more accurate assessment of HER2 ECD levels. Using this refined ass.. Read More»
  DOI: 10.4172/2155-9929.1000151

  Abstract PDF